Stiris Research Inc. hits corporate target of First Site Initiation Visit in a Phase III Global Parkinson’s Study
Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announce that they have successfully achieved a corporate milestone target for a US client of First Site Initiation Visit (“SIV”) in a global Phase III trial in Parkinson’s disease.
“Stiris stepped up to the challenge we set out for them with this corporate milestone, a lot of planning and implementation has gone into study start-up for this trial, and by us achieving our first SIV within this stretch goal is a great success for the company,” said Vice President, Clinical Operations (Client).
“Working to achieve milestones set out by our clients is always paramount for us. Our clients put their trust into us when awarding us their studies, and we fully understand that these milestones are set to allow companies get their products to market as soon as possible. Our clinical team globally has been working tirelessly to get this study activated and this important drug into Parkinson’s patients,” said Amanda Carrera, Vice President, Stiris Research Inc.
About Stiris Research
Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.
For more information, please contact: